Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KMA.CAR-T
- Development stage
- Phase 1
- Lead developer
- HaemaLogiX
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KMA.CAR-T is an investigational chimeric antigen receptor T-cell (CAR-T) therapy designed to treat kappa-type multiple myeloma. It specifically targets the Kappa Myeloma Antigen (KMA), a receptor found exclusively on myeloma cells in patients with kappa-type multiple myeloma, and not on normal immune cells, minimizing off-target effects. The therapy involves collecting a patient's own T cells, genetically engineering them to express a CAR that binds to KMA, expanding these modified cells ex vivo, and then infusing them back into the patient to selectively kill malignant plasma cells. Preclinical studies have demonstrated potent anti-myeloma activity and selective cytotoxicity against KMA-expressing cell lines. The drug is being developed through a collaboration between HaemaLogiX and Peter MacCallum Cancer Centre and has entered Phase 1 clinical trials for relapsed/refractory kappa-type multiple myeloma[1][2][3][6][7][8].
- Other names
- KMA CAR T
02
Targets
Immunoglobulin light chain
Beyond the preview
Go deeper on KMA.CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KMA.CAR-T.